Roth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data

November 29, 2016 11:42 AM EST
Get Alerts VBLT Hot Sheet
Price: $5.05 --0%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VBLT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Roth Capital affirms Vascular Biogenics (Nasdaq: VBLT) with a Buy rating and $17 price target after the company announced top-line results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer.

The firm commented on Tuesday: We believe this is an important update for the thyroid program. Recall that in order to preserve financial resources, future studies in thyroid cancer will be investigator initiated, as it is a rare indication (~2,000 patients in the U.S.) and will have a long trial period. The key focus remains on the Phase III GLOBE study in recurrent GBM as well at the ovarian cancer program. Final data for GLOBE are anticipated in early-2018. In addition, VBLT plans to meet with the FDA before the end of 2016 to discuss the ovarian cancer program.

For an analyst ratings summary and ratings history on Vascular Biogenics Ltd click here. For more ratings news on Vascular Biogenics Ltd click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital

Add Your Comment